Inactive Instrument

XOMA Royalty Corporation Share Price NYSE

XOMAP

US98419J3059

Valuation : XOMA Royalty Corporation

Market Cap	710M 611M 576M 525M 981M 67.9B 990M 6.86B 2.64B 34.44B 2.67B 2.61B 109B	P/E 2024	-15.9x	P/E 2025	18.3x
Enterprise Value	758M 652M 615M 561M 1.05B 72.51B 1.06B 7.33B 2.82B 36.78B 2.85B 2.79B 117B	EV / Sales 2024	11.4x	EV / Sales 2025	7.24x
Free-Float	98.68%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: XOMA Royalty Corporation

Dynamic Chart

Latest news : XOMA Royalty Corporation

09-02	XOMA Royalty Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-14	Ligand Pharmaceuticals Incorporated completed the acquisition of XOMA Royalty Corporation from a group of shareholders.	CI
07-14	Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase	MT
07-14	XOMA Royalty Corp Announces Management Changes	CI
07-14	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from S&P TMI Index	CI
07-14	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from S&P Global BMI Index	CI
07-13	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from NASDAQ Composite Index	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell 3000 Value Benchmark	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Small Cap Comp Value Benchmark	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Small Cap Comp Growth Benchmark	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Microcap Value Benchmark Index	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Microcap Growth Benchmark Index	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell 3000E Value Benchmark	CI

More news

Last Transcript : XOMA Royalty Corporation

Ligand Pharmaceuticals Incorporated, XOMA Royalty Corporation - M&A Call

04-27

More transcripts

Analysts' recommendations : XOMA Royalty Corporation

04-30	HC Wainwright Downgrades XOMA Royalty to Neutral From Buy, Adjusts Price Target to $39 From $97	MT
11-12	Biotech royalty aggregator XOMA reports Q3 net income of $14.1 mln	RE
17/09/25	XOMA Royalty announces closing of tender offer for HilleVax	RE
17/04/25	Benchmark Initiates XOMA Royalty at Buy With $35 Price Target	MT
29/04/24	Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target	MT

More recommendations

Press Releases : XOMA Royalty Corporation

07-14	XOMA Royalty : Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date	PU
07-14	XOMA Royalty Announces Closing of Its Acquisition by Ligand	AQ
06-12	XOMA Royalty : Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator	PU
06-12	XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date	AQ
04-28	XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA	BU

More press releases

News in other languages : XOMA Royalty Corporation

28/10/23	Obseva: Organon rétrocède la licence pour Ebopiprant, paiement d'étape éteint
28/10/23	Obseva: Organon gibt Lizenz für Ebopiprant zurück - Meilensteinanspruch erlischt
15/03/23	Kuros: le déploiement commercial du Magnetos a creusé le déficit en 2022
24/02/23	Obseva réduit la voilure autour de ses actifs restants
19/12/22	Obseva: la demande de retrait de sursis concordataire est acceptée

More news

Managers and Directors : XOMA Royalty Corporation

Manager	Title	Age	Since
Owen Hughes CEO	Chief Executive Officer	51	31/12/2022
Jeffrey Trigilio DFI	Director of Finance/CFO	42	11/01/2026
Bradley Sitko CIO	Chief Investment Officer	45	02/01/2023

More insiders

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Companyâ€™s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Employees

Sector

Entertainment Production

More about the company

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XOMA ROYALTY CORPORATION	+0.04%	+0.08%	-	-	710M
DIVERSIFIED ROYALTY CORP.	+0.49%	-1.91%	+11.72%	+44.37%	557M
FRANCHISE BRANDS PLC	+1.47%	+1.14%	+13.07%	-6.17%	398M
NEXTONE INC.	-2.45%	-2.50%	-8.34%	-4.43%	116M
STERLING GROUP HOLDINGS LIMITED	+6.13%	+28.87%	+650.00%	+837.50%	56.06M
Average	+1.14%	+4.66%	+166.61%	+217.82%	281.93M
Weighted average by Cap.	+0.51%	-0.11%	+41.85%	+60.93%

	2024	2025
Net sales	28.49M 24.5M 23.12M 21.06M 39.36M 2.72B 39.72M 275M 106M 1.38B 107M 105M 4.39B	52.15M 44.85M 42.32M 38.55M 72.06M 4.99B 72.72M 504M 194M 2.53B 196M 192M 8.03B
Net income	-13.82M -11.89M -11.21M -10.22M -19.1M -1.32B -19.27M -134M -51.4M -670M -51.9M -50.77M -2.13B	31.71M 27.27M 25.73M 23.44M 43.82M 3.03B 44.22M 306M 118M 1.54B 119M 116M 4.88B
Net Debt	14.02M 12.05M 11.37M 10.36M 19.37M 1.34B 19.54M 135M 52.13M 680M 52.63M 51.48M 2.16B	48.26M 41.51M 39.16M 35.68M 66.69M 4.61B 67.3M 466M 180M 2.34B 181M 177M 7.43B